Delayed neurotoxicity of intraventricular interleukin-2: A case report
- 1 March 1993
- journal article
- case report
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 15 (3) , 265-267
- https://doi.org/10.1007/bf01050073
Abstract
A case is reported of a 40 year old woman treated with intraventricular IL-2 for leptomeningeal disease who developed progressive cognitive dysfunction. This deterioration started 3 months post-treatment and worsened over the ensuing 4 years. MRI revealed white matter abnormalities that were not present on the pretreatment scan. Although free of disease, the patient has a subcortical dementia and is unable to work. The potential for progressive brain injury and subsequent disability related to intraventricular IL-2 therapy is discussed.Keywords
This publication has 8 references indexed in Scilit:
- Appearance of cytokine-associated central nervous system myelin damage coincides temporally with serum tumor necrosis factor induction after recombinant interleukin-2 infusion in ratsJournal of Neuroimmunology, 1991
- INHIBITION OF INTERLEUKIN-2-INDUCED TUMOR-NECROSIS-FACTOR RELEASE BY DEXAMETHASONE - PREVENTION OF AN ACQUIRED NEUTROPHIL CHEMOTAXIS DEFECT AND DIFFERENTIAL SUPPRESSION OF INTERLEUKIN-2-ASSOCIATED SIDE-EFFECTS1990
- Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects [see comments]Blood, 1990
- Differential central nervous system responses folloqing single and multiple recombinant interleukin-2 infusionsJournal of Neuroimmunology, 1990
- Transient focal neurologic deficits complicating interleukin‐2 therapyNeurology, 1990
- Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrierJournal of Neurosurgery, 1988
- The Neuropsychiatric Effects of Treatment with Interleukin-2 and Lymphokine-Activated Killer CellsAnnals of Internal Medicine, 1987
- INTERLEUKIN-2 OR AUTOLOGOUS LYMPHOKINE-ACTIVATED KILLER-CELL TREATMENT OF MALIGNANT GLIOMA - PHASE-I TRIAL1986